指南与共识泌尿与男性生殖病理

GUPS 更新:肾脏肿瘤的新兴与暂定实体

Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
指南 / 共识 · Mod Pathol · 2021-02-01

泌尿生殖病理学会(GUPS)对 2016 年 WHO 分类后肾脏肿瘤新进展进行批判性综述,强调形态学仍为核心,分子特征日益重要。提出三类新实体:新实体(ESC RCC、RCC FMS、ALK-RCC)、新兴实体(EVT、TLFRCC)和暂定实体(LOT、AKLL、BHP RCC),旨在减少未分类肾癌并指导临床管理。

要点

  • 新实体包括嗜酸性实性囊性 RCC、伴纤维肌瘤间质 RCC 和 ALK 重排相关 RCC。
  • 新兴实体包括嗜酸性空泡状肿瘤和甲状腺样滤泡性 RCC。
  • 暂定实体包括低级别嗜酸细胞肿瘤、萎缩肾样病变和双相透明变性砂粒体性 RCC。

核心结论

  • GUPS 提出肾脏肿瘤新实体、新兴实体和暂定实体的分类框架,以促进识别和减少未分类肾癌。

研究设计与样本

  • GUPS 对 2016 年 WHO 分类后肾脏肿瘤新进展进行批判性综述,基于形态学和分子特征提出分类标准。

主要发现

  • 新实体包括 ESC RCC、RCC FMS(原伴平滑肌间质 RCC)和 ALK-RCC。
  • 新兴实体包括 EVT 和 TLFRCC。
  • 暂定实体包括 LOT、AKLL 和 BHP RCC。

关键数值与推荐

  • 新实体:经多个独立研究验证。
  • 新兴实体:至少两个或以上独立研究提供良好有力数据,但需进一步验证。
  • 暂定实体:仅一或两项研究提供有限数据,需更多工作验证。

临床怎么用

  • 正确诊断可改善预后、指导靶向治疗,并识别遗传或综合征关联以进行适当基因检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Genitourinary Pathology Society (GUPS) undertook a critical review of the recent advances in renal neoplasia, particularly focusing on the newly accumulated evidence post-2016 World Health Organization (WHO) classification. In the era of evolving histo-molecular classification of renal neoplasia, morphology is still key. However, entities (or groups of entities) are increasingly characterized by specific molecular features, often associated either with recognizable, specific morphologies or constellations of morphologies and corresponding immunohistochemical profiles. The correct diagnosis has clinical implications leading to better prognosis, potential clinical management with targeted therapies, may identify hereditary or syndromic associations, which may necessitate appropriate genetic testing. We hope that this undertaking will further facilitate the identification of these entities in practice. We also hope that this update will bring more clarity regarding the evolving classification of renal neoplasia and will further reduce the category of "unclassifiable renal carcinomas/tumors". We propose three categories of novel entities: (1) "Novel entity", validated by multiple independent studies; (2) "Emerging entity", good compelling data available from at least two or more independent studies, but additional validation is needed; and (3) "Provisional entity", limited data available from one or two studies, with more work required to validate them. For some entities initially described using different names, we propose new terminologies, to facilitate their recognition and to avoid further diagnostic dilemmas. Following these criteria, we propose as novel entities: eosinophilic solid and cystic renal cell carcinoma (ESC RCC), renal cell carcinoma with fibromyomatous stroma (RCC FMS) (formerly RCC with leiomyomatous or smooth muscle stroma), and anaplastic lymphoma kinase rearrangement-associated renal cell carcinoma (ALK-RCC). Emerging entities include: eosinophilic vacuolated tumor (EVT) and thyroid-like follicular renal cell carcinoma (TLFRCC). Finally, as provisional entities, we propose low-grade oncocytic tumor (LOT), atrophic kidney-like lesion (AKLL), and biphasic hyalinizing psammomatous renal cell carcinoma (BHP RCC).

来源:Mod Pathol,查看原文。版权归原作者所有。

引用

  1. Trpkov K, Williamson SR, Gill AJ, et al. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021. PMID: 33526874. doi:10.1038/s41379-021-00737-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。